Merrill retains Actelion at neutral

Actelion Ltd. was retained at neutral by Merrill Lynch analysts Erica Whittaker and Peter Welford after the company received an approvable letter instead of FDA approval for Thelin, a drug for pulmonary hypertension. The analysts said that there is speculation this may be linked to a bleeding risk from Thelin's interaction with the anticoagulant warfarin. Merrill said it increased its fair value for Actelion to CHF 126 from CHF 124. Shares of the Baselland, Switzerland, pharmaceutical company closed up CHF 6.60, or 5.37%, at CHF 129.60 on Monday. (Swiss: ALLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.